/Join_Us.gif)
/IMI.jpg)
/Morrison_Foerster.gif)
/Clinical_trial_470_x_80_(new).gif)
Clinical Trials Update provides you with latest news about clinical trials conducted by MVA member companies. The update gives insight to progress in studies, results and possible indications.
ACADIA Pharmaceuticals to Present Data from its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting
16 April - ACADIA Pharmaceuticals will present data from its previously reported Phase II trial with pimavanserin for Parkinson's disease psychosis (PDP) at the 60th American Academy of Neurology Annual Meeting.
The data suggest that pimavanserin, a selective serotonin 5-HT2A inverse agonist that does not block dopamine D2 receptors, may provide antipsychotic benefit to patients with PDP without adversely affecting motor function. In contrast, antipsychotics used off-label for this condition are generally not well tolerated by patients with Parkinson's disease at doses required to achieve antipsychotic effects.
Active Biotech Presents Preclinical Data for their ANYARA Technology
15 April - Active Biotech AB has presented results from pre-clinical studies at the 99th Annual Meeting of the AACR, USA.
The technology behind the project ANYARA; Tumor Targeted Superantigens; "TTS", was studied and evaluated in combination with a standard chemotherapeutic agent, Taxotere (docetaxel). The results of the study demonstrate that TTS therapy is suitable for combination treatment agents such as Taxotere, and suggest a significant potential for such a combination in human cancer therapy.
Biovitrum and Symphogen Initiates a Second Clinical Study with a Novel Treatment of Hemolytic Diseases
15 April - Biovitrum and Symphogen have announced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy volunteers. Clearance of red blood cells by RhD antibodies is an important treatment in preventing hemolytic disease in RhD-positive newborns with RhD-negative mothers.
Sym001 is a new class of biopharmaceuticals for the prevention of hemolytic disease of the newborn by anti-D prophylaxis (ADP), and for the treatment of Idiopathic Thrombocytopenic Purpura (ITP).
Novel Insights into HUMAX-EGFr Mechanisms of Action Published in PNAS
15 April - Genmab A/S (OMX: GEN) has announced new insights showing that HuMax-EGFr (zalutumumab) locks epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective inhibition of cancer cell growth. As EGFr activity plays an important role in many cancers, targeting it with HuMax-EGFr (zalutumumab) should make it especially difficult for cancer cells to grow, multiply, and survive.
These new findings will be published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) in the edition published on April 15, 2008.
Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
14 April - Genentech and Biogen Idec have announced that a Phase II/III study of Rituxan (rituximab) for primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint as measured by the time to confirmed disease progression during the 96-week treatment period. Genentech and Biogen Idec will continue to analyze the study results and will submit the data for presentation at an upcoming medical meeting.
